newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal